Tolinapant for Peripheral T-Cell Lymphoma
This trial is testing a new drug to see if it is safe and effective in treating leukemia.
- Relapsed/Refractory Peripheral T-cell Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any vacancies for people to join this research venture?
"By referencing clinicaltrials.gov, it is apparent that this research endeavour has been open to applicants since June 23rd 2022 and remains active today. The trial was last modified on the 24th of June."
What is the aggregate amount of participants enrolled in this research?
"Affirmative. According to the clinicaltrials.gov site, this research is actively attempting to enroll participants with an initial posting on June 23rd 2022 and a most recent update of June 24th 2022. Thus far, 132 patients have been accepted at one medical centre."